share_log

Athenex, Inc. (NASDAQ:ATNX) Short Interest Update

Athenex, Inc. (NASDAQ:ATNX) Short Interest Update

雅典娜公司 (納斯達克:ATNX) 短期利息更新
Financial News Live ·  2022/12/05 22:52

Athenex, Inc. (NASDAQ:ATNX – Get Rating) was the target of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 3,030,000 shares, a decrease of 12.7% from the October 31st total of 3,470,000 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 2.7 days.

雅典娜公司（NASDAQ：ATNX-獲取評級）是在十一月份短期利益顯著下降的目標。截至十一月十五日，共有 3,030,000 股的短期權益，較十月三十一日共計 3,470,000 股股份下降 12.7%。根據每日平均成交量 1,140,000 股，短息比率目前為 2.7 天。

Athenex Price Performance

雅典娜價格表現

Shares of ATNX stock opened at $0.20 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.49 and a debt-to-equity ratio of 3.08. The business's fifty day simple moving average is $0.21 and its 200-day simple moving average is $0.41. Athenex has a 12-month low of $0.16 and a 12-month high of $1.74.

ATNX 股票的股票在星期一以 0.20 美元開盤。該公司的快速比率為 1.00，流動比率為 1.49，債務與權益比率為 3.08。該業務的五十天簡單移動平均線為 0.21 美元，其 200 天的簡單移動平均線為 0.41 美元。雅典娜擁有 12 個月低點 0.16 美元和 12 個月高點 1.74 美元。

Get
取得
Athenex
雅典娜
alerts:
警報：

Athenex (NASDAQ:ATNX – Get Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02. Athenex had a negative net margin of 145.05% and a negative return on equity of 727.79%. The company had revenue of $33.53 million for the quarter, compared to analyst estimates of $28.80 million. During the same period in the prior year, the company earned ($0.33) earnings per share. As a group, analysts expect that Athenex will post -0.63 earnings per share for the current year.

雅典娜 (NASDAQ: ATNX — 獲得評分) 上次公佈其季度收益業績週四, 11 月 3 日.該公司報告了本季度每股收益（0.14 美元），超過了 0.02 美元的共識估計（0.16 美元）。雅典娜的負淨利潤率為 145.05%，負資產回報率為 727.79%。該公司本季度的收入為 33.53 億美元，而分析師估計為 28.80 萬美元。在上一年同期，該公司每股盈利（0.33 美元）。作為一個集團，分析師預計 Athenex 將在本年度每股盈利 -0.63。

Institutional Trading of Athenex

雅典娜機構交易

Hedge funds have recently bought and sold shares of the business. Millennium Management LLC increased its holdings in Athenex by 104.1% in the 2nd quarter. Millennium Management LLC now owns 4,578,195 shares of the company's stock valued at $1,874,000 after purchasing an additional 2,335,225 shares during the last quarter. Perceptive Advisors LLC raised its stake in Athenex by 14.8% during the 3rd quarter. Perceptive Advisors LLC now owns 15,532,467 shares of the company's stock worth $4,178,000 after acquiring an additional 2,000,000 shares in the last quarter. Victory Capital Management Inc. raised its stake in Athenex by 15,027.3% during the 3rd quarter. Victory Capital Management Inc. now owns 1,616,203 shares of the company's stock worth $435,000 after acquiring an additional 1,605,519 shares in the last quarter. Empery Asset Management LP acquired a new stake in Athenex during the 3rd quarter worth $391,000. Finally, UBS Group AG increased its stake in Athenex by 173.3% in the third quarter. UBS Group AG now owns 1,496,764 shares of the company's stock valued at $403,000 after purchasing an additional 949,096 shares during the period. Institutional investors and hedge funds own 29.41% of the company's stock.
對沖基金最近買賣了該業務的股票。千禧管理有限責任公司在第二季度將其在雅典娜的持有量增加了 104.1％。千禧管理有限責任公司現在擁有該公司 4,578,195 股股票，價值為 1,874,000 美元，在上一季度額外購買 2,335,225 股股票後。感知顧問有限責任公司在雅典娜的股份上調了 14.8% 在第三季度.洞察力顧問有限責任公司現在擁有該公司股票的 15,532,467 股價值 4,178,000 美元在上個季度獲得了額外的 2,000,000 股之後。勝利資本管理公司在第三季度提高了其在雅典娜的股份 15,027.3％。勝利資本管理公司現在擁有該公司股票的 1,616,203 股，價值 435,000 美元，在上一季度額外收購了 1,605,519 股股份。英皇資產管理有限責任公司在第三季度收購了雅典娜的新股份，價值 391,000 美元。最後，瑞銀集團股份公司在第三季度將其在雅典娜的股份增加了 173.3%。瑞銀集團股份有限公司在期內額外購買 949,096 股股份後，現擁有該公司股票的 1,496,764 股價值 403,000 美元。機構投資者和對沖基金擁有公司股票的 29.41％。

About Athenex

關於雅典娜

(Get Rating)

(取得評分)

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies.

Athenex, Inc. 是一家生物製藥公司，致力於治療癌症的藥物的發現、開發和商業化。它通過三個部分運營：腫瘤學創新平台，全球供應鏈平台和商業平台。該公司的 Orascovery 產品候選產品包括口服紫杉醇和 encequidar，口服劑型，這是一種用於轉移性乳腺癌的第三期試驗，以及皮膚血管瘤，晚期胃癌和晚期固體惡性腫瘤的各種臨床研究。

Read More

閱讀更多

  • Get a free copy of the StockNews.com research report on Athenex (ATNX)
  • Is Salesforce Stock a Bargain Down Here?
  • Intel is a Sleeping Giant Ready to Awaken
  • Why CSL Ltd Stock Could Be Worth a Look
  • MarketBeat: Week in Review 11/28 – 12/02
  • Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
  • 獲取有關雅典娜研究報告的免費副本
  • 銷售力量股票在這裡討價還價嗎？
  • 英特爾是一個沉睡的巨人準備喚醒
  • 為什麼 CSL 有限公司股票值得一看
  • 市場節拍：評論中的一周
  • Okta Inc 慶祝盈利節拍，但他們可以維持提升嗎？

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

接收雅典娜日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Athenex 及相關公司的最新新聞和分析師評級的簡要每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論